Results 201 to 210 of about 42,056 (305)

GV1001 Reprograms CD47 Immune Checkpoint to Restore Macrophage Antitumor Activity in Oral Squamous Cell Carcinoma. [PDF]

Int J Mol Sci
Chen W, Kim S, Beheshtian C, Jun A, Kim S, Park NH.   +5 more
europepmc   +1 more source

RNA Modifications: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 5, May 2026.
Types of RNA modification. We have summarized the currently common types of RNA modifications, including ac4C, m6A, m1A, m5C, m3C, m7G, and ψ, and visually characterized their features through structural formulas. The characteristic structures are marked with a background color different from the background color.
Shiyu Xiao, Tingwen Xiang, Chuan Yang, Xiaohua Wang, Gang Huang, Fei Luo, Zhao Xie, Yueqi Chen   +7 more
wiley   +1 more source

CD47 as a prognostic biomarker and potential immunotherapy target in penile squamous cell carcinoma. [PDF]

Sci Rep
Zhang J, Hu X, Xu J, Ai C, Wang H, Xie X, Ao Y, Tan J, Jin J, Liu G, Huang Y, Lan W.   +11 more
europepmc   +1 more source

Expression of mouse CD47 on human cancer cells profoundly increases tumor metastasis in murine models [PDF]

, 2015

core   +1 more source

Targeting Tumor Stroma: Current Challenges and Future Directions

MedComm, Volume 7, Issue 5, May 2026.
Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang, Haofan Hu, Weifeng Zeng, Lu Qin, Xiaoping Chen, Zhibin Liao, Furong Liu, Zhanguo Zhang   +7 more
wiley   +1 more source

Establishment of Predictive Models for Second Hepatoma Recurrence. [PDF]

Cancer Manag Res
Su M, Zhong W, Chen Z, Zhang G.
europepmc   +1 more source

Efferocytosis: Signaling Pathways and New Therapeutic Strategies for Diseases

MedComm, Volume 7, Issue 5, May 2026.
1. Efferocytosis coordinates molecular signaling and metabolic reprogramming to resolve inflammation. 2. Efferocytosis dysfunction underlies four conserved pathological hallmarks across diseases. 3. Therapeutic strategies targeting efferocytosis should be context‐dependent: enhance or inhibit based on disease type. ABSTRACT Efferocytosis—the phagocytic
Lei Wang, Jingjing Ge, Zehua Wang, Yihua Fang, Yongxu Jia, Ruyue Zhang, Yanru Qin   +6 more
wiley   +1 more source

Photodynamic therapy with zinc phthalocyanine suppresses immune checkpoints in human melanoma cells. [PDF]

Lasers Med Sci
Doustvandi MA, Hajizadeh M, Mohammadnejad F, Karamali N, Yari AH, Nobari SA, Baradaran B.   +6 more
europepmc   +1 more source

A Biomimetic Micro‐Nano System Maximizing ‘Active Transport and Retention’ Effect in Solid Tumors

Small, Volume 22, Issue 25, 4 May 2026.
The Active Transport and Retention (ATR) strategy is realized using a biomimetic micro‐nano system (PG@BAM‐LRC), achieving superior tumor accumulation and efficacy in low‐EPR pancreatic tumors. Platelet (PG)‐derived microcarriers enable tumor‐homing and MMP‐9‐responsive release of nanoliposomes (LRC), while berbamine (BAM) promotes transendothelial ...
Kaiyun Yang, Jiajia Su, Alan J. Davidson, Zimei Wu, Wenli Zhang   +4 more
wiley   +1 more source

PAARH suppresses Kupffer cell phagocytosis to promote tumor liver metastasis by upregulating CD47. [PDF]

Cancer Cell Int
Li W, Wei Y, Lu R, Tan G, Lu X, Lin J, Tan C, Wei H, Deng C, Wei Z, Pu J.   +10 more
europepmc   +1 more source